Viral Hepatitis: The Silent Disease That Can Lead to Liver Cancer
Viral hepatitis, particularly types B and C, are silent infections that affect the liver and can go unnoticed for years. These infections are major global causes of liver cancer, according to the WHO, making their asymptomatic nature particularly dangerous. In Brazil, millions are unknowingly living with hepatitis B or C, and late diagnosis presents a significant challenge to disease control, potentially leading to severe, irreversible consequences if left untreated.
Early stages of hepatitis B and C often lack symptoms, or present with non-specific signs like abdominal pain, nausea, malaise, fatigue, fever, dizziness, and nausea, which can be mistaken for other conditions. When symptoms do appear, they might lead individuals to seek emergency care, where diagnosis can occur. Untreated hepatitis B and C can progress to hepatocellular carcinoma, the most common type of primary liver cancer. This progression is typically slow, emphasizing the critical importance of early detection before irreversible liver damage occurs.
Prevention strategies include vaccination against hepatitis B, available free of charge through Brazil's public health system for all age groups. However, individuals vaccinated should confirm the vaccine's efficacy by checking for protective antibodies. There is currently no vaccine for hepatitis C, necessitating regular testing for those potentially exposed. The use of condoms and avoiding the sharing of needles are crucial preventive measures for both types of hepatitis and other sexually transmitted infections. The Ministry of Health recommends hepatitis B and C testing for all adults, especially those who have never been tested, pregnant women, individuals with a history of blood transfusions before 1993, and those who have shared needles or sharp objects. Tests are quick, simple, and accessible at public health units. Early treatment of hepatitis B and C can prevent progression to cirrhosis and liver cancer; hepatitis C is curable with medication, while hepatitis B can be managed with medical supervision to preserve liver function.
Viral hepatitis B and C represent a significant public health challenge due to their often asymptomatic nature, leading to delayed diagnosis and increased risk of liver cancer. The availability of a free hepatitis B vaccine through public health services is a key preventive measure, yet ensuring its effectiveness through antibody testing is an often-overlooked step. For hepatitis C, the absence of a vaccine places a greater emphasis on diagnostic testing and accessible treatment, with recent advancements offering a cure. The systemic approach to combating these diseases involves not only medical interventions but also public awareness campaigns promoting safe practices and regular screening, particularly for at-risk populations. Future strategies should focus on enhancing diagnostic accessibility and treatment adherence, leveraging technological advancements to improve early detection and management, thereby mitigating the long-term burden of liver disease and cancer.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.